Form D · Biotechnology

REGENXBIO Inc.

Rockville, MD · CIK 0001590877

Offering snapshot reported May 28, 2015 · SEC filing

Reported sold
$70.5M
Offering amount: $70.5M
Investors reported
36
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
May 15, 2015
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
May 28, 2015Initial$70,500,008No comparison36SEC filing
Jan 23, 2015Initial$27,500,002No comparison15SEC filing
Nov 7, 2013Initial$7,891,875No comparison3SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$2.33M
Finders' fees
$0
Form D file number
021-240664

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Chardan Capital Markets, LLC120128Chardan Capital Markets, LLC · CRD 120128

Source: Form D, filed May 28, 2015. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Benjamin Auspitz Director
Luke Beshar Director
Allan M. Fox Director
Don Hayden Director
Donald J. Hayden, Jr. Director
Daniel Kiser Director
John Daniel Kiser Director
Kenneth T. Mills Director, Executive
Camille Samuels Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
9712 Medical Center Drive Suite 100
Rockville, MD, 20850